Patents by Inventor Shulu FENG

Shulu FENG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240148732
    Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.
    Type: Application
    Filed: January 25, 2022
    Publication date: May 9, 2024
    Inventors: Shulu FENG, Morgan LAWRENZ, Jiaye GUO, Goran KRILOV, Andrew PLACZEK, Zhe NIE, Lynnie TRZOSS, Haifeng TANG, Pieter Harm BOS, Michael TRZOSS, Shelby ELLERY
  • Publication number: 20240018157
    Abstract: The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof which are MALT1 inhibitors. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and pharmaceutically acceptable salts thereof, and methods of using the compounds and compositions for treating diseases, such as cancer, autoimmune disorders, and inflammatory disorders.
    Type: Application
    Filed: December 24, 2020
    Publication date: January 18, 2024
    Inventors: Shulu Feng, Morgan Lawrenz, Goran Krilov, Andrew Placzek, Zhe Nie, Lynnie Trzoss, Michael Trzoss, Haifeng Tang, H. Rachel Lagiakos
  • Publication number: 20230286960
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.
    Type: Application
    Filed: April 18, 2023
    Publication date: September 14, 2023
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Markus K. DAHLGREN, Shulu FENG, Aleksey I. GERASYUTO, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Anke KLIPPEL-GIESE, Jennifer Lynn KNIGHT, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, David L. MCELLIGOTT, Johnathan Alexander MCLEAN, Loredana PUCA, Kannan Karukurichi RAVI, Daniel Lee SEVERANCE, Michael Brian WELCH, Tien WIDJAJA
  • Patent number: 11649227
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: May 16, 2023
    Assignee: Petra Pharma Corporation
    Inventors: Erin Danielle Anderson, Sean Douglas Aronow, Nicholas A. Boyles, Markus K. Dahlgren, Shulu Feng, Aleksey I. Gerasyuto, Eugene R. Hickey, Thomas Combs Irvin, Edward A. Kesicki, Anke Klippel-Giese, Jennifer Lynn Knight, Gabrielle R. Kolakowski, Manoj Kumar, Katelyn Frances Long, Christopher Glenn Mayne, David L. McElligott, Johnathan Alexander McLean, Loredana Puca, Kannan Karukurichi Ravi, Daniel Lee Severance, Michael Brian Welch, Tien Widjaja
  • Publication number: 20220372023
    Abstract: The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): or a prodrug, solvate, enantiomer, stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, W, X, Y, s, and Ring A are as described herein.
    Type: Application
    Filed: April 2, 2021
    Publication date: November 24, 2022
    Inventors: Erin Danielle ANDERSON, Sean Douglas ARONOW, Nicholas A. BOYLES, Markus K. DAHLGREN, Shulu FENG, Aleksey I. GERASYUTO, Eugene R. HICKEY, Thomas Combs IRVIN, Edward A. KESICKI, Anke KLIPPEL-GIESE, Jennifer Lynn KNIGHT, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, David L. MCELLIGOTT, Johnathan Alexander MCLEAN, Loredana PUCA, Kannan Karukurichi RAVI, Daniel Lee SEVERANCE, Michael Brian WELCH, Tien WIDJAJA